Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report)‘s stock had its “market outperform” rating reiterated by equities researchers at JMP Securities in a research note issued on Friday, Benzinga reports. They presently have a $22.00 target price on the biotechnology company’s stock. JMP Securities’ price target would indicate a potential upside of 118.91% from the stock’s […]

Astria Therapeutics (NASDAQ:ATXS – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report issued on Friday, Benzinga reports. They currently have a $16.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 43.63% from the stock’s previous close. A […]

Legend Biotech (NASDAQ:LEGN – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Royal Bank of Canada in a report released on Friday, Benzinga reports. They currently have a $86.00 target price on the stock. Royal Bank of Canada’s target price would indicate a potential upside of 74.55% from the stock’s current […]

Research analysts at StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS – Get Free Report) in a note issued to investors on Thursday. The firm set a “sell” rating on the biotechnology company’s stock. A number of other equities analysts have also commented on the company. Oppenheimer lowered their price objective on Cellectis from $11.00 […]

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $40.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 46.84% from the […]